Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3794-3802

  Puzanov, Igor ^a   Lee, Wooin ^b   Chen, Alice P ^c   Calcutt, M Wade ^a   Hachey, David L ^a   Vermeulen, Wendy L ^a   Spanswick, Victoria J ^d   Liao, Chih Yi ^a   Hartley, John A ^d   Berlin, Jordan D ^a   Rothenberg, Mace L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b University of Kentucky   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; NSC 694501; SJG 136; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; COLON CANCER; DISTRIBUTION VOLUME; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; LEIOMYOSARCOMA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; OSTEOSARCOMA; OVARY CANCER; PARAGANGLIOMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; THYROID CANCER; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; BENZODIAZEPINONES; DEXAMETHASONE; DYSPNEA; EDEMA; FATIGUE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRROLES;

EID: 79955802388     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2056     Document Type: Article

References (12)

1. Lawley PD, Phillips DH. DNA adducts from chemotherapeutic agents. Mutat Res 1996;355:13-40. (Pubitemid 26275502)
2. Reddy BS, Sondhi SM, Lown JW. Synthetic DNA minor groove-binding drugs. Pharmacol Ther 1999;84:1-111. (Pubitemid 29486667)
3. Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, et al. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem 2001;44:737-48.
4. Clingen PH, De Silva IU, McHugh PJ, Ghadessy FJ, Tilby MJ, Thurston DE, et al. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c] [1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res 2005;33:3283-91.
5. Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004;64:6693-9. (Pubitemid 39297932)
6. Alley MC, Hollingshead MG, Pacula-Cox CM, Waud WR, Hartley JA, Howard PW, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations. Cancer Res 2004;64:6700-6. (Pubitemid 39297933)
7. Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P, et al. Phase I study of a sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res 2009;15:2140-7.
8. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47. (Pubitemid 27337928)
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
10. Wade Calcutt M, Lee W, Puzanov I, Rothenberg ML, Hachey DL. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom 2008;43:42-52. (Pubitemid 351251972)
11. Spanswick VJ, Hartley JM, Ward TH, Hartley JA. Measurement of drug-induced DNA interstrand crosslinking using the single cell gel electrophoresis (comet) assay. In: Brown R and Boger-Brown U, editors. Methods in molecular medicine, vol. 28: cytotoxic drug resistance mechanisms. Springer: Humana Press; 1999. p. 143-54.
12. Wilkinson GP, Taylor JP, Shnyder S, Cooper P, Howard PW, Thurston DE, et al. Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA -cross-linking agent. Invest New Drugs 2004;22:231-40. (Pubitemid 39012562)